甲状腺相关眼病 (TAO)是Graves病中一种毁容和潜在致盲的自身免疫成分。它似乎至少部分是由针对促甲状腺素受体 (TSHR)/胰岛素样生长因子I受体 (IGF-IR ...

IGF-II通过IGF-IIR发挥神经保护 杏仁核注射IGF-II可使焦虑行为改善率达75%，但IGF-IR抑制剂JB1无阻断效应。 相反，IGF-IIR抗体完全逆转IGF-II疗效，并抑制AKT-mTOR通路激活，证实IGF-IIR是核心作用靶点。

Tepezza是美国 FDA 批准的第一种也是唯一一种治疗TED的药物，于2020年1月获批上市，该药是一种全人单克隆抗体（mAb）和胰岛素样生长因子-1受体（IGF-1R ...

Phosphorylation-deficient mutation of residue Tyr1131 in IGF-IR or Tyr1146 in InsR abrogates the activation of IGF-IR/InsR by mTOR. Finally, overexpression of rictor promotes IGF-induced cell ...

一方面，通过提升肝脏细胞表面的生长激素受体（GHR）数量和敏感性，提高IGF-1表达水平、促进肝脏分泌更多IGF-1；另一方面，通过提升骨骺端生长板 ...

THRIVE是迄今为止在TED患者中进行的最大规模的抗IGF-1R抗体3期临床试验之一，共纳入了113名中度至重度活动性TED患者，被随机分配接受Veligrotug或安慰 ...

Elimination of IGF-IR expression results in variable tumor regression To examine whether mammary tumors initiated by IGF-IR overexpression (Jones et al., 2007) require continuous IGF-IR signaling ...

IGF-1生长因子增敏剂，是一种指能够提升机体组织对IGF-1利用效率的分子、蛋白等活性成分。 作用原理 IGF-1，即胰岛素样生长因子-1（Insulin-like Growth ...

The type 1 insulin-like growth factor I (IGF-IR) receptor plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials.

In some cases, this is due to a change in the signaling pathways, such as when IRS-1 transforms the IGF-IR from a receptor that causes differentiation to a mitogenic receptor.